SEARCH

SEARCH BY CITATION

References

  • 1
    Rosenbaum P, Paneth N, Leviton A, Goldstein M, Bax M. A report: the definition and classification of cerebral palsy. Dev Med Child Neurol2007; 49(Suppl. 109): 814.
  • 2
    Cans C. Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and registers. Dev Med Child Neurol2000; 42: 81624.
  • 3
    Odding E, Roebroeck ME, Stam HJ. The epidemiology of cerebral palsy: incidence, impairments and risk factors. Disabil Rehabil2006; 28: 18391.
  • 4
    Mutch L. Cerebral palsy epidemiology: where are we now and where are we going?Dev Med Child Neurol1992; 34: 547.
  • 5
    Sankar C, Mundkur N. Cerebral palsy – definition, classification, etiology and early diagnosis. Indian J Pediatr2005; 72: 8658.
  • 6
    Howard J, Soo B, Graham HK, et al.Cerebral palsy in Victoria: motor types, topography and gross motor function. J Paediatr Child Health2005; 41: 47983.
  • 7
    Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol1997; 39: 21423.
  • 8
    Wood E, Rosenbaum P. The Gross Motor Function Classification System for cerebral palsy: a study of reliability and stability over time. Dev Med Child Neurol2000; 42: 2926.
  • 9
    Sanger TD, Delgado MR, Gaebler-Spira D, Hallett M, Mink JW, Task Force on Childhood Motor Disorders. Classification and definition of disorders causing hypertonia in childhood. Pediatrics2003; 111: e8997.
  • 10
    Watson L, Blair E, Stanley FJ. Report of the Western Australian Cerebral Palsy Register to Birth Year 1999. Perth: Telethon Institute for Child Health Research, 2006.
  • 11
    Goldstein EM. Spasticity management: an overview. J Child Neurol2001; 16: 1623.
  • 12
    Ann HT. Management of spasticity in children with cerebral palsy. Semin Pediatr Neurol2004; 11: 5865.
  • 13
    Lamanna C, Carr CJ. The botulinal, tetanal, and enterostaphylococcal toxins: a review. Clin Pharmacol Ther1967; 8: 286332.
  • 14
    de Paiva A, Meunier FA, Molgó J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA1999; 96: 32005.
  • 15
    Duchen LW, Strich SJ. The effects of botulinum toxin on the patterns of innervation of skeletal muscle in the mouse. Exp Physiol1968; 53: 849.
  • 16
    Koog YH, Min B-I. Effects of botulinum toxin A on calf muscles in children with cerebral palsy: a systematic review. Clin Rehabil2010; 24: 685700.
  • 17
    Ryll U, Bastiaenen C, De Bie R, Staal B. Effects of leg muscle botulinum toxin A injections on walking in children with spasticity-related cerebral palsy: a systematic review. Dev Med Child Neurol2011; 53: 2106.
  • 18
    Fehlings D, Novak I, Berweck S, Hoare B, Stott NS, Russo RN. Botulinum toxin assessment, intervention and follow-up for paediatric upper limb hypertonicity: international consensus statement. Eur J Neurol2010; 17(Suppl. 2):3856.
  • 19
    Love SC, Novak I, Kentish M, et al.Botulinum toxin assessment, intervention and after-care for lower limb spasticity in children with cerebral palsy: international consensus statement. Eur J Neurol2010; 17(Suppl. 2): 937.
  • 20
    Cosgrove AP, Corry IS, Graham HK. Botulinum toxin in the management of the lower limb in cerebral palsy. Dev Med Child Neurol1994; 36: 38696.
  • 21
    Koman LA, Mooney JF 3rd, Smith B, Goodman A, Mulvaney T. Management of cerebral palsy with botulinum-A toxin: preliminary investigation. J Pediatr Orthop1993; 13: 48995.
  • 22
    Darrah J, Hickman R, O’Donnell M, Vogtle L, Wiart L. AACPDM methodology to develop systematic reviews of treatment interventions (Revision 1.2). 2008. http://www.aacpdm.org (accessed 30 June 2012).
  • 23
    Arens LJ, Leary PM, Goldschmidt RB. Experience with botulinum toxin in the treatment of cerebral palsy. S Afr Med J1997; 87: 10013.
  • 24
    Barwood S, Baillieu C, Boyd R, et al.Analgesic effects of botulinum toxin A: a randomized, placebo-controlled clinical trial. Dev Med Child Neurol2000; 42: 11621.
  • 25
    Coutinho dos Santos LH, Bufara Rodrigues DC, Simoes de Assis TR, Bruck I. Effective results with botulinum toxin in cerebral palsy. Pediatr Neurol2011; 44: 35763.
  • 26
    Fattal-Valevski A, Giladi N, Domanievitz D, et al.Parameters for predicting favorable responses to botulinum toxin in children with cerebral palsy. J Child Neurol2002; 17: 2727.
  • 27
    Fragala MA, O’Neil ME, Russo KJ, Dumas HM. Impairment, disability, and satisfaction outcomes after lower-extremity botulinum toxin A injections for children with cerebral palsy. Pediatrics2002; 14: 13244.
  • 28
    Gooch JL, Sandell TV. Botulinum toxin for spasticity and athetosis in children with cerebral palsy. Arch Phys Med Rehabil1996; 77: 50811.
  • 29
    Jung NH, Heinen F, Westhoff B, et al.Hip lateralisation in children with bilateral spastic cerebral palsy treated with botulinum toxin type A: a 2-year follow-up. Neuropediatrics2011; 42: 1823.
  • 30
    Linder M, Schindler G, Michaelis U, et al.Medium-term functional benefits in children with cerebral palsy treated with botulinum toxin type A: 1-year follow-up using gross motor function measure. Eur J Neurol2001; 8(Suppl. 5): 1206.
  • 31
    Lundy CT, Doherty GM, Fairhurst CB. Botulinum toxin type A injections can be an effective treatment for pain in children with hip spasms and cerebral palsy. Dev Med Child Neurol2009; 51: 70510.
  • 32
    Mall V, Heinen F, Kirschner J, et al.Evaluation of botulinum toxin A therapy in children with adductor spasm by gross motor function measure. J Pediatr Neurol2000; 15: 21417.
  • 33
    Mall V, Heinen F, Linder M, Philipsen A, Korinthenberg R. Treatment of cerebral palsy with botulinum toxin A: functional benefit and reduction of disability. Three case reports. Pediatr Rehabil1997; 1: 2357.
  • 34
    Manzano FS, Granero LM, Masiero D, dos Maria TBR. Treatment of muscle spasticity in patients with cerebral palsy using BTX-A: a pilot study. Spec Care Dentist2004; 24: 2359.
  • 35
    Meholjic A, Madjar D. Application of botulinum toxin in treatment of spasticity and functional improvements for children suffering from cerebral palsy. Med Arch2010; 64: 35961.
  • 36
    Papavasiliou AS, Rapidi C-A, Filiopoulos C, Rizou C, Skouteli HN. Evaluation of a multimodal management of prematurity-related spasticity. Pediatr Neurol2006; 35: 4007.
  • 37
    Vles GF, de Louw AJA, Speth LA, et al.Visual analogue scale to score the effects of botulinum toxin A treatment in children with cerebral palsy in daily clinical practice. Eur J Paediatr Neurol2008; 12: 2318.
  • 38
    Weigl DM, Arbel N, Katz K, Becker T, Bar-On E. Botulinum toxin for the treatment of spasticity in children: attainment of treatment goals. J Pediatr Orthop B2007; 16: 2936.
  • 39
    Wong V. Use of botulinum toxin injection in 17 children with spastic cerebral palsy. Pediatr Neurol1998; 18: 12431.
  • 40
    Nolan KW, Cole LL, Liptak GS. Use of botulinum toxin type A in children with cerebral palsy. Phys Ther2006; 86: 57384.
  • 41
    Scrutton D, Baird G. Surveillance measures of the hips of children with bilateral cerebral palsy. Arch Dis Child1997; 76: 3814.
  • 42
    Dobson F, Boyd RN, Parrott J, Nattrass GR, Graham HK. Hip surveillance in children with cerebral palsy: impact on the surgical management of spastic hip disease. J Bone Joint Surg Br2002; 84: 7206.
  • 43
    Soo B, Howard JJ, Boyd RN, et al.Hip displacement in cerebral palsy. J Bone Joint Surg Am2006; 88: 1219.
  • 44
    Graham HK, Boyd R, Carlin JB, et al.Does botulinum toxin A combined with bracing prevent hip displacement in children with cerebral palsy and ‘hips at risk’? A randomized, controlled trial. J Bone Joint Surg Am2008; 90: 2333.
  • 45
    Hanna SE, Rosenbaum PL, Bartlett DJ, et al.Stability and decline in gross motor function among children and youth with cerebral palsy aged 2 to 21 years. Dev Med Child Neurol2009; 51: 295302.
  • 46
    Palisano RJ, Cameron D, Rosenbaum PL, Walter SD, Russell D. Stability of the gross motor function classification system. Dev Med Child Neurol2006; 48: 4248.
  • 47
    Haley SM, Coster WJ, Ludlow LH, Haltiwanger JT, Andrellos PJ. Pediatric Evaluation of Disability Inventory (PEDI). Development, Standardisation and Administration Manual. Boston, MA: Department of Rehabilitation Medicine, New England Medical Center Hospital, 1992.
  • 48
    Molenaers G, Desloovere K. Pharmacologic treatment with botulinum toxin. In: Gage JR, Schwartz MH, Koop SE, Novacheck TF, editors. The Identification and Treatment of Gait Problems in Cerebral Palsy, 2nd edn. London: Mac Keith Press, 2009: 36380.
  • 49
    Runu R, Agrawal V, Swaroop A, Dave D. Botulinum toxin as treatment modality for spastic diplegic cerebral palsy child: our experience in 21 patients. Indian J Physiother Occup Ther2011; 5: 69.
  • 50
    Esquenazi A, Novak I, Sheean G, Singer B, Ward A. International consensus statement for the use of botulinum toxin treatment in adults and children with neurological impairments – introduction. Eur J Neurol2010; 17(Suppl. 2): 18.